Skip to content
Biodatica
Start free

PDX PHARMACEUTICALS, INC.

Portland, OR

OncologyRNAiGrant-only
Compare Sign in to watch

What changed

NIH R44 · $1.3M · PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer

12mo agoGrant renewalJul 23, 2025Source filing (opens the source filing in a new tab)

Momentum

32no change

Momentum 32 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,925 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    SB1 · $89k · non-dilutive

    Sep 5, 2024

    PDX PHARMACEUTICALS, INC. · PI NGAMCHERDTRAKUL, WORAPOL · NCI · award ends Aug 31, 2026 · Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment

    NIH RePORTER · NIH RePORTER 11184418 (opens the source filing in a new tab)

  2. Grant

    R44 · $1.3M · non-dilutive

    Jul 6, 2023

    PDX PHARMACEUTICALS, INC. · PI NGAMCHERDTRAKUL, WORAPOL · NCI · award ends Aug 31, 2027 · PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer

    NIH RePORTER · NIH RePORTER 11179339 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources